55 Cambridge Parkway
Tel: 857-999 0075
Fax: 866-553 3269
82 articles with KalVista Pharmaceuticals
KVD900 Phase 2 On Track to Begin in 2018 for Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema
The gross proceeds to KalVista from the offering are expected to be approximately $68.0 million
The 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018, at 3:40 p.m. ET in New York, NY.
KVD900 Selected to Advance to Phase 2 as Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema (HAE)
KalVista Pharmaceuticals, Inc. announced that it will present a corporate overview at the Jefferies Healthcare Conference.
KalVista Pharmaceuticals Presents Data at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
KalVista Pharmaceuticals, Inc. announced data from a poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 in Munich, Germany.
A Global Awareness Day for a Rare Life-Threatening Condition
KalVista Pharmaceuticals Presents Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting
KalVista Pharmaceuticals, Inc. announced data in support of the Company’s development activities in diabetic macular edema (DME) from an oral presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting in Honolulu, Hawaii.
Both trials commenced in December 2017, in line with KalVista’s previously stated 2017 objectives.
Revenue was $1.1 million for the three months ended October 31, 2017, compared to $0.2 million for the same period in 2016.
KalVista Pharmaceuticals Provides Operational Update And Reports Fiscal Fourth Quarter And Full Year Financial Results
KalVista Pharmaceuticals Announces Initiation Of A Phase 1 Clinical Trial Of KVD818 For The Treatment Of Hereditary Angioedema